UNSPSC 51383406: Proglumetacin maleate

This classification denotes an indoleacetic acid and non-steroidal anti-inflammatory agent with the molecular formula C46H58ClN5O8, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier FV919079LU, chemically known as 3-(4-(2-hydroxyethyl)-1-piperazinyl)propyl dl-4-benzamido-n,n-dipropylglutaramate 1-(p-chlorobenzoyl)-5-methoxy-2-methylindole-3-acetate (ester) but more generally known as proglumetacin, which bears US NIH Compound Identifier 4921.

UNSPSC 51383406 Proglumetacin maleate is a Commodity code that in practice captures state and local procurement of pharmaceuticals and related health products, though the recent opportunities under this code show little activity in proglumetacin specifically and instead reflect broader patterns in generic multi-source pharmaceuticals, naloxone products, and therapeutic pharmacy initiatives. State and local issuers soliciting under this code span county health departments, state health and human services agencies, and cooperative purchasing alliances serving multiple jurisdictions. The work being solicited includes procurement of generic pharmaceuticals with specified National Drug Codes (NDCs), naloxone and drug deactivation systems for community health initiatives, and direct-to-manufacturer prescription fulfillment arrangements designed to improve cost management and supply-chain efficiency.

Recent activity appears concentrated in Florida, Minnesota, and Texas. Seminole County, Florida issued IFB 60459723LAS in June 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, with bids due July 26, 2023. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP (S1070000015802) posted January 20, 2026 for generic multi-source pharmaceuticals and OTC products to be distributed across participating state and local facilities including Oregon, with proposals due March 26, 2026 and contract effectiveness July 1, 2026; vendors must supply through three authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health 110 and 112, and Morris & Dickson Co., LLC) and maintain commercial general liability of $5 million per occurrence and network security and privacy liability of $2 million. The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to gather market intelligence on direct-to-manufacturer prescription programs and vendor capacity to contract outside traditional pharmacy benefit managers and group purchasing organizations, with no formal award or budget announced at the RFI stage.